Yang Xueqing, Deng Xi, Wu Meiqing, Chen Sean W, Jiang Muliang, Long Liling, Chen Bihong T
Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.
Insights Imaging. 2024 Feb 14;15(1):40. doi: 10.1186/s13244-024-01605-y.
Primary central nervous system post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare but serious complication of hematopoietic stem cell transplantation (HSCT) in patients with severe β-thalassemia. This study aimed to assess the clinical presentation, pathological characteristics, neuroimaging findings, and treatment strategies in patients with β-thalassemia who developed PCNS-PTLD and to compare a case series from our transplant center to reported cases from literature.
We retrospectively reviewed our hospital database and identified four cases of pathologically confirmed PCNS-PTLD without a history of systemic PTLD in patients with severe β-thalassemia after HSCT. We also performed a relevant literature review on PCNS-PTLD.
The median time from transplantation to diagnosis of PCNS-PTLD was 5.5 months. Intracerebral lesions were usually multiple involving both supratentorial and infratentorial regions with homogeneous or rim enhancement. All patients had pathologically confirmed PCNS-PTLD with three patients having diffuse large B-cell lymphoma and the fourth patient having plasmacytic hyperplasia. There was low response to treatment with a median survival of 83 days.
PCNS-PTLD should be considered in the differential diagnosis of patients with β-thalassemia who had an intracranial lesion on neuroimaging after HSCT.
This case series with a comprehensive review of neuroimaging and clinical characteristics of children with primary central nervous system post-transplantation lymphoproliferative disorder should advance our understanding and improve management of this rare yet severe complication following transplant for β-thalassemia.
• We assessed clinical presentation, treatment strategies, and neuroimaging characteristics of PCNS-PTLD in patients with β-thalassemia after transplantation. • Patients with β-thalassemia may have post-transplantation lymphoproliferative disorder presenting as brain lesions on neuroimaging. • Neuroimaging findings of the brain lesions are helpful for prompt diagnosis and proper management.
原发性中枢神经系统移植后淋巴组织增生性疾病(PCNS-PTLD)是重型β地中海贫血患者造血干细胞移植(HSCT)后一种罕见但严重的并发症。本研究旨在评估发生PCNS-PTLD的β地中海贫血患者的临床表现、病理特征、神经影像学表现及治疗策略,并将我们移植中心的一系列病例与文献报道的病例进行比较。
我们回顾性分析了我院数据库,确定了4例重型β地中海贫血患者HSCT后经病理确诊为PCNS-PTLD且无系统性PTLD病史的病例。我们还对PCNS-PTLD进行了相关文献回顾。
从移植到诊断为PCNS-PTLD的中位时间为5.5个月。脑内病变通常为多发,累及幕上和幕下区域,呈均匀或环状强化。所有患者经病理确诊为PCNS-PTLD,3例为弥漫性大B细胞淋巴瘤,第4例为浆细胞增生。治疗反应不佳,中位生存期为83天。
对于HSCT后神经影像学检查发现颅内病变的β地中海贫血患者,鉴别诊断时应考虑PCNS-PTLD。
本病例系列对原发性中枢神经系统移植后淋巴组织增生性疾病患儿的神经影像学和临床特征进行了全面回顾,应能增进我们对这种罕见但严重的β地中海贫血移植后并发症的理解,并改善其管理。
• 我们评估了移植后β地中海贫血患者PCNS-PTLD的临床表现、治疗策略和神经影像学特征。• β地中海贫血患者移植后淋巴组织增生性疾病可能表现为神经影像学检查发现的脑病变。• 脑病变的神经影像学表现有助于及时诊断和正确管理。